ReviewFEBS letters2026
STING agonists as antiviral agents.
Review in FEBS letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Herpes Simplex Virus Type 1 (HSV-1) UL38 Capsid Protein: A Promising Target Against Viral Infection.Viruses · 2026Article
- Opening the black box: insights into ubiquitin-mediated control of innate antiviral immunity and AI-enhanced therapeutics.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway plays a pivotal role in mounting an innate immune response against invading pathogens. Activation of this pathway by exogenous or endogenous stimuli triggers the downstream production of interferons and both pro-/anti-inflammatory cytokines. Over the past decade, hundreds of patents have been filed for the development and use of natural and synthetic STING agonists. For antivirals, synthetic STING agonists have been shown to be effective in both prophylactic and anaphylactic manners against viral infection and serve as vaccine adjuvants. This review summarizes the current application of STING agonists as antivirals to date against a variety of RNA and DNA viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.